Raymond James Financial Inc. Buys New Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James Financial Inc. acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 41,592 shares of the life sciences company's stock, valued at approximately $943,000. Raymond James Financial Inc. owned approximately 0.05% of Integra LifeSciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Nisa Investment Advisors LLC grew its position in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter worth approximately $180,000. Centiva Capital LP acquired a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $192,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $204,000. Finally, Romano Brothers AND Company acquired a new position in Integra LifeSciences in the 4th quarter worth approximately $204,000. 84.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average price target of $23.00.

Remove Ads

Integra LifeSciences Stock Up 0.1 %

NASDAQ IART traded up $0.01 during trading on Monday, reaching $19.58. The company's stock had a trading volume of 768,282 shares, compared to its average volume of 1,045,522. The stock has a market capitalization of $1.51 billion, a PE ratio of -217.53, a PEG ratio of 0.73 and a beta of 1.24. The business has a 50-day moving average price of $23.37 and a 200-day moving average price of $22.34. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $34.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period last year, the business earned $0.89 EPS. The firm's revenue was up 11.5% compared to the same quarter last year. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.